Characterization for Novel Biotherapeutics
Workflows, Strategies, and Technologies for Analyzing Emerging Protein Modalities
5/13/2027 - May 14, 2027 ALL TIMES EDT
Rapid innovation in protein engineering is driving an explosion of new antibody and protein formats—from bispecifics and T cell engagers to Fc-engineered antibodies, alternative antibody scaffolds, and engineered enzyme therapeutics, alongside next-generation antibody-drug, oligonucleotide, and radionuclide conjugates. The Characterization for Novel Biotherapeutics conference will spotlight the analytical strategies, regulatory expectations, and quality frameworks needed to evaluate these complex products. Sessions will explore chain-pairing and mispairing analytics for bispecific and multispecific formats, effector function and half-life characterization for engineered Fc and fusion proteins, and advances in linker, payload, and conjugation-site characterization for emerging antibody conjugates. Attendees will also gain insight into strategies for building a characterization approach from scratch on molecules that don't fit any established format. This program offers a comprehensive look at how cutting-edge analytics are enabling the next generation of protein therapeutics to reach patients safely and efficiently.
Preliminary Agenda

PLENARY FIRESIDE CHAT

Panel Moderator:

PANEL DISCUSSION: From Discovery to Impact: Perspectives from a Patient Advocate and a Patient-Cohort Leader on Accelerating Therapeutic Innovation

Jane Osbourn, PhD, CEO, Alchemab Therapeutics Ltd. , CEO , Alchemab Therapeutics

Panelists:

Debra Miller, Founder & CEO, CureDuchenne , Founder & CEO , CureDuchenne

Craig Ritchie, PhD, CEO & Founder, Scottish Brain Sciences , Founder & CEO , Scottish Brain Sciences

CHARACTERIZATION OF NOVEL BISPECIFIC AND MULTISPECIFIC FORMATS

KEYNOTE PRESENTATION: From Data to Decisions: Large-Scale Data Generation and AI Models for Multi-specific Developability Prediction

Photo of Norbert Furtmann, PhD, Head, Biologics AI & Design, Computational and AI Strategy, Sanofi , Global Head of Biologics AI & Design , Computational and AI Strategy , Sanofi
Norbert Furtmann, PhD, Head, Biologics AI & Design, Computational and AI Strategy, Sanofi , Global Head of Biologics AI & Design , Computational and AI Strategy , Sanofi

Characterization of Multispecifics using Orthogonal Analytical Technologies: A Focus on the Development of Cancer Biotherapeutics

Photo of Elsa Gore, PhD, Senior Principal Scientist, Cell Engineering & Analytical Sciences, Johnson & Johnson Innovative Medicine , Senior Principal Scientist , Cell Engineering & Analytical Sciences , Johnson & Johnson Innovative Medicine
Elsa Gore, PhD, Senior Principal Scientist, Cell Engineering & Analytical Sciences, Johnson & Johnson Innovative Medicine , Senior Principal Scientist , Cell Engineering & Analytical Sciences , Johnson & Johnson Innovative Medicine

Bispecific and multispecific antibody therapeutics pose complex expression and quality challenges that require orthogonal, high-resolution analytics during cell line development. We present an integrated multiparametric platform combining peptide quantitation, native SEC-FLR-MS, subunit mass analysis to accelerate clone selection and identify product-related variants. Absolute quantitation of co-expressed chains guided plasmid ratio adjustments to reduce heavy-chain overexpression and fragment formation. Native SEC-FLR-MS enabled fluorescence quantitation and mass identification of heterodimer, oligomers, and fragments. Subunit analysis with complementary enzymatic digests deconvoluted higher-order aggregates, revealing origins of aggregation. These orthogonal readouts deliver mechanistic insight to inform construct, clone, and process decisions.

Analytical Characterization of Reduced Proteolytic Clipping in CHO Culture via HAI-1 Overexpression

Photo of Gregory Pirrone, PhD, Principal Scientist, Analytical Research & Development, Merck Research Labs , Principal Scientist , Analytical R&D , Merck & Co., Inc.
Gregory Pirrone, PhD, Principal Scientist, Analytical Research & Development, Merck Research Labs , Principal Scientist , Analytical R&D , Merck & Co., Inc.

Proteolytic degradation of recombinant proteins in Chinese hamster ovary (CHO) cells remains a major challenge in biopharmaceutical manufacturing, often reducing product yield and quality. In this work, overexpressing hepatocyte growth factor activator inhibitor-1 (HAI-1) mitigates matriptase-1-mediated degradation in CHO cells. Utilizing an IL-12 IgG1 Fc-fusion and a multispecific antibody as model proteins, analytical characterization confirmed that this engineered protease control strategy preserves critical quality attributes, maintaining viability and cellular growth.

NOVEL BISPECIFIC AND MULTISPECIFIC FORMATS (CONTINUED)

Protein A Membrane Chromatography Enables High-Throughput Polishing for Small-Scale Manufacturing of Complex Bispecific Antibodies

Photo of Zheng David Cai, Principal Scientist, Biotherapeutics Discovery, Boehringer Ingelheim Intl GmbH , Principal Scientist , Biotherapeutics Discovery , Boehringer Ingelheim Pharmaceuticals, Inc
Zheng David Cai, Principal Scientist, Biotherapeutics Discovery, Boehringer Ingelheim Intl GmbH , Principal Scientist , Biotherapeutics Discovery , Boehringer Ingelheim Pharmaceuticals, Inc

Structural Insights into the Binding Geometries and Mechanistic Functionality of Novel Fab-Based Bivalent Bispecific Antibodies

Photo of Steven J. Frey, PhD, Senior Scientist, AstraZeneca , Senior Scientist , Protein Engineering and Novel Modalities, Biologics Engineering , AstraZeneca
Steven J. Frey, PhD, Senior Scientist, AstraZeneca , Senior Scientist , Protein Engineering and Novel Modalities, Biologics Engineering , AstraZeneca

Bispecific antibody architecture influences function, motivating the development of diverse formats. Here we present the design and characterization of Duet 2+2, a highly developable Fab-based bivalent bispecific antibody platform. To demonstrate its functional utility, we show that two distinct geometric variants, Duet 2+2 Symmetric and Duet 2+2 Asymmetric, retain potent neutralizing activity against a SARS-CoV-2 variant that compromises both the parental antibody cocktail and the corresponding monovalent bispecific DuetMab. Cryo-EM and structural modeling of intact Duet 2+2 in complex with SARS-CoV-2 spike suggest this functional advantage can be attributed to Duet 2+2 architecture, which facilitates multivalent, avidity-driven binding.

Novel Characterization Methods to Support Design of Bispecifics to Overcome Challenges with Stability, Solubility, and Cross-interactions

Photo of Hassan Shahfar, PhD, Senior Postdoctoral Researcher, Roberts Lab, University of Delaware , Senior Postdoctoral Researcher , Roberts Lab , University of Delaware
Hassan Shahfar, PhD, Senior Postdoctoral Researcher, Roberts Lab, University of Delaware , Senior Postdoctoral Researcher , Roberts Lab , University of Delaware

NEW AND NOVEL ANTIBODY CONJUGATES

Catabolite Identification in ADCs Using a Non-Targeted Mass Spectrometry Approach

Hamidreza Ardalani, Senior Scientist, Merck & Co. , Senior Scientist , Merck & Co.

Understanding the biotransformation of antibody-drug conjugates (ADCs) is important for evaluating their activity and safety. We developed a mass spectrometry-based assay to identify and characterize ADC catabolites formed in biologically relevant systems. Using high-resolution LC-MS and MS/MS, the assay enables characterization of released payloads and linker-payload species, providing insights into ADC biotransformation and supporting bioanalytical strategies during drug discovery and development.

Beyond Cytotoxics: Rethinking ADC Design, Conjugation, and Characterization

Photo of Elena Petricci, PhD, Associate Professor, Organic Chemistry, University of Siena , Associate Professor , Organic Chemistry , University of Siena
Elena Petricci, PhD, Associate Professor, Organic Chemistry, University of Siena , Associate Professor , Organic Chemistry , University of Siena

Antibody-drug conjugates (ADCs) rely mostly on cytotoxic payloads for cancer therapy. This presentation will cover ADCs with unconventional payloads, novel linker–payload systems, and innovative bioconjugation strategies, characterized by HIC, UV–Vis, NMR, and SDS-PAGE to assess drug loading, integrity, and stability. A machine-learning model predicting the drug-to-antibody ratio (DAR) from linker–payload and antibody features will be introduced, showing how integrating chemistry, analytics, and computation can extend ADCs beyond oncology.

Beyond Intact-Molecule Attributes: Payload-Level Characterization of Antibody-Drug Conjugate Photostability

Photo of Yifei Wang, PhD, Principal Scientist, Bristol Myers Squibb , Principal Scientist , Bristol Myers Squibb
Yifei Wang, PhD, Principal Scientist, Bristol Myers Squibb , Principal Scientist , Bristol Myers Squibb

Antibody-drug conjugate quality is typically assessed through antibody attributes together with conjugate-specific measures such as drug-to-antibody ratio and free drug. Light exposure was found to compromise attached payload in ways none of these attributes capture. A payload-level approach was developed and qualified to characterize this liability, and mechanistic investigation identified the potential underlying structural change. Findings informed product development decisions and support payload-level stability assessment for photosensitive conjugates.

CHARACTERIZATION OF THERAPEUTIC PEPTIDES

Discovery of De Novo Binders Targeting HIV-Restricted Peptides for Bispecific T-Cell Engager Development

Photo of Xinran An, Graduate Researcher, Biomedical & Chemical & Biomolecular Engineering, Johns Hopkins University , Graduate Student , Biomedical & Chemical & Biomolecular Engineering , Johns Hopkins Univ
Xinran An, Graduate Researcher, Biomedical & Chemical & Biomolecular Engineering, Johns Hopkins University , Graduate Student , Biomedical & Chemical & Biomolecular Engineering , Johns Hopkins Univ

To eliminate the latent HIV viral reservoir and develop a universal immunotherapy, we aim to engineer novel bispecific T-cell engagers (BiTEs) that target HIV peptide-loaded HLA-E complexes on infected CD4+ T cells. We generated yeast-displayed libraries presenting computationally designed minibinders and performed iterative selections. From these libraries, we identified a binder against an HIV peptide-loaded HLA-E complex with high peptide specificity, which was used as the basis for BiTE design.

Engineering Peptides at the Speed of Light

Photo of Ken Lo, PhD, Principal Scientist II, Small Molecule Therapeutics and Platform Technologies, AbbVie Inc. , Principal Scientist II , Small Molecule Therapeutics and Platform Technologies , AbbVie Inc
Ken Lo, PhD, Principal Scientist II, Small Molecule Therapeutics and Platform Technologies, AbbVie Inc. , Principal Scientist II , Small Molecule Therapeutics and Platform Technologies , AbbVie Inc

CHARACTERIZATION STRATEGIES FOR NEW MODALITIES

Proteoform-Resolved HCP Characterization by Mass Spectrometry: New Applications for Biologics Process Development

Photo of Vishnu Priya Mohan, Scientist, Analytical Development, Takeda , Scientist , Analytical Dev , Takeda Pharmaceutical Co Ltd
Vishnu Priya Mohan, Scientist, Analytical Development, Takeda , Scientist , Analytical Dev , Takeda Pharmaceutical Co Ltd

Rethinking Renal Filtration of Novel Formats: How Shape, Structure, and FcRn Binding Affinity Dictate Clearance

Hanine Rafidi, PhD, Principal Scientist, Translational PK/PD, Genentech Inc. , Principal Scientist , Translational PK/PD , Genentech Inc

Presentation to be Announced


For more details on the conference, please contact:
Kent Simmons
Senior Conference Director
Cambridge Healthtech Institute
Phone: 207-329-2964
Email: [email protected]

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5452
Email: [email protected]

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: 781-972-1340
Email: [email protected]


Register

View By:


Premier Sponsors

Biointron_new       Kactus